v3.25.4
Shareholders’ Equity
12 Months Ended
Dec. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Shareholders’ Equity Shareholders’ Equity
The rights of the holders of Class A common stock and Class B common stock are identical, except with respect to voting
and conversion rights. Each share of Class A common stock is entitled to one vote per share. Each share of Class B
common stock is entitled to ten votes per share and is convertible into one share of Class A common stock. During 2025
and 2024, Class B shareholders elected to convert their shares to Class A. Total conversions from Class B to Class A shares
were 826,316 and 3,181,149 for the years ended December 31, 2025 and 2024, respectively.
In October 2025, holders of our Class A common stock have the ability to tokenize their shares on the Solana blockchain
through our co-transfer agent, Superstate. The tokenized common stock is recorded and maintained by the co-transfer agent
and represents the same ownership interests as the corresponding shares of Class A common stock reflected in the
company’s official share register.
In December 2024, our Class A common stock was listed for quotation on the NYSE American under the symbol
“EXOD”.
In April 2024, our Class A common stock was listed for quotation on the OTCQX under the symbol “EXOD”. OTC
Markets approval was received in April 2024.
In January 2024, our Class A common stock was listed for quotation on the OTCQB under the symbol “EXOD”. OTC
Markets approval was received in January 2024 and in January the initial qualifying deposit was made and initial trades
have occurred.
Share-Based Compensation
Options and Equity Grants Issued
The 2019 Equity Incentive Plan adopted in September 2019 (the “2019 Plan”) permitted the Company to grant non-
statutory stock options, incentive stock options, and other equity awards to Exodus team members, directors, and
consultants. The exercise price for options issued under the 2019 Plan is determined by the Board, but will be (i) in the case
of an incentive stock option granted to an employee or consultant who owns stock representing more than 10% of the
voting power of all classes of stock of Exodus, no less than 110% of the fair market value per share on the date of grant; or
(ii) granted to any other team member or consultant, no less than 100% of the fair market value per share on the date of
grant. The contractual life for all options issued under the 2019 Plan is 10 years. The 2019 Plan authorized grants to issue
up to 3,000,000 options (prior to the 2021 Equity Incentive Plan) that are convertible into shares of authorized but unissued
Class B common stock. As of December 31, 2025, there were 545,142 shares of Class B common stock options
outstanding.
In August 2021, the Company adopted the 2021 Equity Incentive Plan, as amended and restated (the "Plan"). The Plan
permits the Company to grant non-statutory stock options, incentive stock options and other equity awards, such as
restricted stock units, to Exodus team members, directors, and consultants. The exercise price for options issued under the
2021 Plan is determined by the board of directors, but will be (i) in the case of an incentive stock option granted to an team
member who owns stock representing more than 10% of the voting power of all classes of stock of Exodus, no less than
110% of the fair market value per share on the date of grant; or (ii) granted to any other team member or consultant, no less
than 100% of the fair market value per share on the date of grant. The contractual life for all options issued under the 2021
Plan is 10 years. The Plan initially authorized grants to issue up to 2,780,000 awards that are convertible into shares of
authorized but unissued Class A common stock. Pursuant to the terms of the Plan, the Company may increase our share
pool by 5% of our outstanding shares of capital stock each year. As of December 31, 2024, a total of 6,662,936 shares of
Class A common stock were reserved for issuance under the Plan. In August 2025, the Company added 1,453,470
additional shares to the share pool in accordance with the Evergreen provision, bringing the total number of shares reserved
for issuance under the Plan to 8,116,406 as of December 31, 2025. As of December 31, 2025, there were 2,543,468
restricted stock units that are authorized and outstanding with a fair value of $37.6 million.
Upon the approval of the Amended Plan, the Company can no longer grant non-statutory stock options, incentive stock
options, or other equity awards to Exodus team members, directors, or consultants under the 2019 Plan.
The terms of our share-based compensation are governed by the plan pursuant to which such awards were issued.
The following table summarizes stock option activities for 2025:
Options
Weighted Average
Exercise Price
Outstanding - beginning of period
866,135
$2.41
Exercised
(320,993)
$2.40
Outstanding - end of period
545,142
$2.41
The following table summarizes RSU activities for 2025:
RSUs
Weighted Average
Grant Date Fair Value Price
Outstanding - beginning of period
2,904,901
$4.14
Granted
1,270,707
$26.20
Vested
(1,414,455)
$8.46
Forfeited
(217,685)
$9.35
Outstanding - end of period
2,543,468
$12.13
Share-based compensation for the years ended December 31, 2025 and 2024 is recorded on the Company’s consolidated
statements of operations and comprehensive (loss) income as follows:
(in thousands)
2025
2024
Technology, development, and user support
$6,733
$2,829
General and administrative
7,604
4,328
Share-based compensation
$14,337
$7,157
As of December 31, 2025, total unrecognized share-based compensation expense was $13.8 million. This compensation
expense is expected to be recognized over a weighted-average period of 1.6 years.
Warrants
During the year ended December 31, 2025, the Company issued warrants to purchase 100,000 shares of its common stock
to a third-party; no cash was received or paid in connection with the issuance. The fair value of the warrants was recorded
to general and administrative expense on the consolidated statements of operations and comprehensive (loss) income and a
corresponding increase to additional paid-in capital. For the year ended December 31, 2025, the expense related to the
issuance of the warrants was $2.0 million using the Black-Scholes option-pricing model, based on the following weighted-
average assumptions:
December 31, 2025
Exercise price
$31.90
Risk-free interest rate
4.03%
Expected dividend yield
Expected volatility
81.32%
Expected life (years)
7.0